Company news
Clarity Pharmaceuticals Ltd. (ASX:CU6) news
Clarity Pharmaceuticals Ltd. news releases on 6ix. Latest, Feb 19, 2025: Clarity receives US FDA Fast Track Designation for the treatment of metastatic…
Press releases — page 2
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
February 19, 2025
Clarity receives US FDA FTD for the treatment of mCRPC
February 18, 2025
Clarity expands pipeline with Cu-64/67 SAR-trastuzumab
February 10, 2025
Clarity to present COBRA and CLARIFY abstracts
January 27, 2025
Clarity receives U.S. FDA Fast Track Designation
January 23, 2025
Novel FAP-targeted radiopharmaceutical
December 17, 2024
S&P DJI Announces December 2024 Quarterly Rebalance
December 6, 2024
Last patient assessment completed for SARTATE trial
November 27, 2024
First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA
November 25, 2024
Chairperson Address AGM
November 19, 2024
Head-to-head IIT with SAR-bisPSMA
November 17, 2024
Clarity and Nucleus RadioPharma sign MSA
November 10, 2024
Copper-67 SAR-bisPSMA updates
October 15, 2024
Positive guidance from the US FDA on Phase III trial
October 13, 2024
Michelle Parker Promoted to CEO
October 13, 2024
Shareholder briefing - presentation
September 18, 2024
SECuRE trial advances
September 11, 2024
S&P DJI Announces September 2024 Quarterly Rebalance
September 6, 2024
FDA Fast Track Designation 64CU-SAR-bisPSMA
August 22, 2024
Supply agreement for Ac-225 with TerraPower Isotopes
July 15, 2024
Clarity strengthens Cu-64 network with new supply agreement
May 29, 2024
Complete response with Cu-67 SAR-bisPSMA
April 29, 2024
Successful Completion of Retail Entitlement Offer
April 24, 2024
Despatch of Retail Entitlement Offer Booklet
April 3, 2024
Completion of Placement and Institutional Entitlement Offer
March 27, 2024
Investor Presentation
March 25, 2024
Clarity launches $121 million equity raise
March 25, 2024
Trading Halt
March 24, 2024
First participant treated in the last dose escalation cohort
March 21, 2024
Theranostic prostate cancer trial advances to multi-dose
March 15, 2024
Additional COBRA trial data results
March 5, 2024
S&P DJI Announces March 2024 Quarterly Rebalance
March 1, 2024
Initial COBRA results
February 14, 2024
First patient dosed in Phase III prostate cancer trial
December 21, 2023
Recruitment closes for a diagnostic Phase II trial in NETs
December 18, 2023
Phase III CLARIFY trial in prostate cancer commences
November 29, 2023
undetectable PSA level with Cu-67 SAR-bisPSMA
November 29, 2023
SECuRE theranostic prostate cancer trial progresses
November 29, 2023
Bell Potter Healthcare Conference Presentation
November 14, 2023
Recruitment target achieved for Phase II SAR-Bombesin trial
November 6, 2023
Presentation for Wilsons Drug and Device Conference
October 26, 2023
First patient treated with Cu-67 SAR-Bombesin
October 2, 2023
Company Presentation E&P Small Cap Healthcare Conference
September 12, 2023
BOP preliminary trial results presented at EANM 2023
September 12, 2023
First neuroblastoma participant treated in highest cohort
August 25, 2023
First PC participant treated at the highest dose level
August 24, 2023
Theranostic prostate cancer trial advances to cohort 3
August 9, 2023
Clarity Bolsters Antibody Pre-Targeting with IP from MSK
August 6, 2023
Final Cohort opens for CL04 Paediatric Neuroblastoma trial
July 25, 2023
Phase II SABRE prostate cancer trial reaches 50% recruitment
July 23, 2023